These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 29367052)
1. Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of Helicobacter pylori. Luo M; Jia YY; Jing ZW; Li C; Zhou SY; Mei QB; Zhang BL Colloids Surf B Biointerfaces; 2018 Apr; 164():11-19. PubMed ID: 29367052 [TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of novel pH-sensitive ureido-conjugated chitosan/TPP nanoparticles targeted to Helicobacter pylori. Jing ZW; Jia YY; Wan N; Luo M; Huan ML; Kang TB; Zhou SY; Zhang BL Biomaterials; 2016 Apr; 84():276-285. PubMed ID: 26851392 [TBL] [Abstract][Full Text] [Related]
3. Anti-Helicobacterpylori effectiveness and targeted delivery performance of amoxicillin-UCCs-2/TPP nanoparticles based on ureido-modified chitosan derivative. Jing ZW; Luo M; Jia YY; Li C; Zhou SY; Mei QB; Zhang BL Int J Biol Macromol; 2018 Aug; 115():367-374. PubMed ID: 29660462 [TBL] [Abstract][Full Text] [Related]
4. Development of novel pH-sensitive thiolated chitosan/PMLA nanoparticles for amoxicillin delivery to treat Helicobacter pylori. Arif M; Dong QJ; Raja MA; Zeenat S; Chi Z; Liu CG Mater Sci Eng C Mater Biol Appl; 2018 Feb; 83():17-24. PubMed ID: 29208276 [TBL] [Abstract][Full Text] [Related]
5. Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori. Jain SK; Haider T; Kumar A; Jain A AAPS PharmSciTech; 2016 Oct; 17(5):1131-40. PubMed ID: 26566630 [TBL] [Abstract][Full Text] [Related]
6. Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori. Lotfipour F; Valizadeh H; Milani M; Bahrami N; Ghotaslou R Drug Res (Stuttg); 2016 Jan; 66(1):41-5. PubMed ID: 25919643 [TBL] [Abstract][Full Text] [Related]
7. Nanoparticles incorporated in pH-sensitive hydrogels as amoxicillin delivery for eradication of Helicobacter pylori. Chang CH; Lin YH; Yeh CL; Chen YC; Chiou SF; Hsu YM; Chen YS; Wang CC Biomacromolecules; 2010 Jan; 11(1):133-42. PubMed ID: 19924885 [TBL] [Abstract][Full Text] [Related]
8. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin. Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176 [TBL] [Abstract][Full Text] [Related]
9. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab. Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558 [TBL] [Abstract][Full Text] [Related]
10. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery. Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238 [TBL] [Abstract][Full Text] [Related]
11. Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection. Tan Z; Liu W; Liu H; Li C; Zhang Y; Meng X; Tang T; Xi T; Xing Y Eur J Pharm Biopharm; 2017 Feb; 111():33-43. PubMed ID: 27865932 [TBL] [Abstract][Full Text] [Related]
12. CS/PAA@TPGS/PLGA nanoparticles with intracellular pH-sensitive sequential release for delivering drug to the nucleus of MDR cells. Wang YY; Zhang DD; Kong YY; Shao LL; Zhang FY; Gao Y; Mu X; Wang J; Li HF; Yu SQ; Xu Q Colloids Surf B Biointerfaces; 2016 Sep; 145():716-727. PubMed ID: 27289313 [TBL] [Abstract][Full Text] [Related]
13. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705 [TBL] [Abstract][Full Text] [Related]
14. Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system. Wang H; Liu J; Tao S; Chai G; Wang J; Hu FQ; Yuan H Int J Nanomedicine; 2015; 10():5671-85. PubMed ID: 26388691 [TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Wang H; Agarwal P; Zhao S; Xu RX; Yu J; Lu X; He X Biomaterials; 2015 Dec; 72():74-89. PubMed ID: 26344365 [TBL] [Abstract][Full Text] [Related]
16. Surface-functionalized, pH-responsive poly(lactic-co-glycolic acid)-based microparticles for intranasal vaccine delivery: Effect of surface modification with chitosan and mannan. Li Z; Xiong F; He J; Dai X; Wang G Eur J Pharm Biopharm; 2016 Dec; 109():24-34. PubMed ID: 27569030 [TBL] [Abstract][Full Text] [Related]
17. Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Lin YH; Tsai SC; Lai CH; Lee CH; He ZS; Tseng GC Biomaterials; 2013 Jun; 34(18):4466-79. PubMed ID: 23499480 [TBL] [Abstract][Full Text] [Related]
18. Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. Pandit J; Sultana Y; Aqil M Artif Cells Nanomed Biotechnol; 2017 Nov; 45(7):1397-1407. PubMed ID: 27855494 [TBL] [Abstract][Full Text] [Related]
19. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Parveen S; Sahoo SK Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969 [TBL] [Abstract][Full Text] [Related]
20. Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori. Ramteke S; Ganesh N; Bhattacharya S; Jain NK J Drug Target; 2009 Apr; 17(3):225-34. PubMed ID: 19241256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]